Amplatzer Amulet China Post Market Study (PMS)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device.

Clinical Trial Description

Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. During AF, chaotic electrical activity results in rapid, uncoordinated, and insufficient contractions of the atrial chambers. Stagnation of blood flow in the left atrium (LA) can lead to hypercoagulability. The left atrial appendage (LAA), given its location and complex shape is often the primary site of stasis and thus increases the risk for thrombus formation. Approximately 90% of all thrombi in patients with non-valvular AF (NVAF) forming in the LA originate in the LAA. Patients with NVAF are at an increased risk of systemic embolism and stoke due to the potential for clot forming in the LAA. OAC is the recommended first-line therapy for NVAF at increased risk of stroke, however, many patients have relative or absolute contraindications to taking OACs. LAAO offers a non-pharmacological option for stroke risk reduction in these patients unable to take OAC. The Amulet occluder is Abbott's second-generation LAA occlusion device. It received CE Mark in 2013, and FDA approval in August 2021. Observational studies performed in multiple geographies show that the Amulet occluder can be safely implanted with good procedural outcomes and reduce the risk of stroke as compared to a predicted rate without the need for anticoagulation in most patients. This led to the National Medical Products Administration (NMPA) approval of the Amulet occluder in 2020. The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06189365
Study type	Observational
Source	Abbott Medical Devices
Contact	Rio ZHAN
Phone	+86 21 2320 4181
Email	wanlei.zhan@abbott.com
Status	Recruiting
Phase
Start date	January 30, 2024
Completion date	January 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02502396` - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Withdrawn	`NCT03508258` - Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
Terminated	`NCT03715725` - A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Active, not recruiting	`NCT05565599` - An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation	N/A
Completed	`NCT02756481` - Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela	N/A
Completed	`NCT04193826` - The Conformal Prague Study	N/A
Completed	`NCT01884350` - Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)	Phase 4
Completed	`NCT02422602` - Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program	N/A
Recruiting	`NCT02147444` - Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation	N/A
Completed	`NCT01857622` - Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment	Phase 3
Recruiting	`NCT04829929` - Evaluation od Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk	N/A
Recruiting	`NCT05761704` - Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation	N/A
Recruiting	`NCT04559243` - Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
Completed	`NCT03570047` - Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
Terminated	`NCT03204695` - WAVECREST Post Market Clinical Follow-Up (PMCF) Study	N/A
Completed	`NCT04722679` - A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Completed	`NCT04297072` - Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists
Recruiting	`NCT05320627` - Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation	Phase 4
Recruiting	`NCT03088072` - A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure	Phase 4
Completed	`NCT04519944` - Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention